Radiometer’s AQT90 FLEX immunoassay analyzer has been identified by the Innovative Technology Adoption Procurement Programme (iTAPP) as being significant to the NHS Quality, Innovation, Productivity and Prevention (QIPP) agenda, with the benefits it offers to the wider health economy being explored at local, regional and national level.
Diagnosis and treatment of patients presenting to emergency departments, coagulation clinics or early pregnancy units is highly dependent on prompt receipt of pathology results.
The AQT90 FLEX analyzer’s advanced technology allows rapid, laboratory standard testing of a comprehensive panel of cardiac markers, as well as D-dimer, CRP and β-hCG, at the point of care.
The fully automated process uses a closed tube system, eliminating time-consuming manual sample preparation and reducing the risk of staff coming into contact with biological fluids.
Accurate results are consistently generated in less than 20 minutes, enabling faster diagnosis and treatment, and prompt clinical decision making.
This capability - allowing clinicians to quickly rule in or out conditions such as acute coronary syndrome, congestive heart failure, DVT, pulmonary embolisms, acute infections and pregnancy - significantly improves productivity, and patient management and outcomes.
The AQT90 Briefing Pack, published through the NHS Technology Adoption Centre, has been fully integrated into the NICE Health Technologies Adoption Programme, providing comprehensive documentation that demonstrates how the system can yield real, significant and sustainable benefits for local healthcare services.